Analysts at Robert W. Baird Reiterated their Past ‘”Buy”’ rating on Shares PRA Health Sciences (NASDAQ:PRAH), Set a $94.0 Price Target

March 14, 2018 - By Ivan Hodges

 Analysts at Robert W. Baird Reiterated their Past ‘

PRA Health Sciences (NASDAQ:PRAH) Rating Reaffirmed

The broker has just set a target price of $94.0 on PRA Health Sciences (NASDAQ:PRAH) shares. This is 3.64 % from the last price. In a note revealed to investors on Thursday, 30 November, Robert W. Baird maintained their “Buy” rating on shares of PRAH.

PRA Health Sciences, Inc. (NASDAQ:PRAH) Ratings Coverage

Among 15 analysts covering PRA Health Sciences (NASDAQ:PRAH), 10 have Buy rating, 0 Sell and 5 Hold. Therefore 67% are positive. PRA Health Sciences has $110.0 highest and $43 lowest target. $92.08’s average target is 1.52% above currents $90.7 stock price. PRA Health Sciences had 42 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Equal-Weight” rating by First Analysis on Tuesday, June 21. The stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) earned “Buy” rating by SunTrust on Monday, March 28. KeyBanc Capital Markets upgraded PRA Health Sciences, Inc. (NASDAQ:PRAH) on Monday, June 13 to “Overweight” rating. MUFG Securities Americas Inc initiated PRA Health Sciences, Inc. (NASDAQ:PRAH) on Thursday, December 14 with “Buy” rating. The rating was downgraded by Mizuho to “Neutral” on Wednesday, January 24. UBS downgraded the shares of PRAH in report on Tuesday, September 6 to “Neutral” rating. The rating was maintained by Credit Suisse with “Buy” on Monday, October 16. Credit Suisse maintained PRA Health Sciences, Inc. (NASDAQ:PRAH) on Tuesday, August 8 with “Outperform” rating. The rating was upgraded by Credit Suisse on Monday, February 6 to “Outperform”. Credit Suisse initiated it with “Neutral” rating and $43 target in Tuesday, June 21 report.

The stock decreased 1.59% or $1.47 during the last trading session, reaching $90.7. About 389,012 shares traded. PRA Health Sciences, Inc. (NASDAQ:PRAH) has risen 52.22% since March 14, 2017 and is uptrending. It has outperformed by 35.52% the S&P500.

Analysts await PRA Health Sciences, Inc. (NASDAQ:PRAH) to report earnings on April, 24. They expect $0.77 EPS, up 28.33 % or $0.17 from last year’s $0.6 per share. PRAH’s profit will be $49.12M for 29.45 P/E if the $0.77 EPS becomes a reality. After $1.04 actual EPS reported by PRA Health Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.96 % negative EPS growth.

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company has market cap of $5.79 billion. The firm offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It has a 68.71 P/E ratio. It also provides product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

More recent PRA Health Sciences, Inc. (NASDAQ:PRAH) news were published by: which released: “PRA Health Sciences Receives CRO Leadership Award” on March 14, 2018. Also published the news titled: “PRA Health Sciences Named Best CRO in Asia” on March 06, 2018.‘s news article titled: “Pre-Market Technical Scan on Medical Research Equities — HTG Molecular …” with publication date: March 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.